Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

RenovoRx (RNXT) Gains from Sales and Divestitures (2024 - 2025)

RenovoRx's Gains from Sales and Divestitures history spans 2 years, with the latest figure at $4.0 million for Q3 2025.

  • For Q3 2025, Gains from Sales and Divestitures rose 80540.0% year-over-year to $4.0 million; the TTM value through Sep 2025 reached $4.0 million, up 80540.0%, while the annual FY2024 figure was $5000.0, N/A changed from the prior year.
  • Gains from Sales and Divestitures for Q3 2025 was $4.0 million at RenovoRx, up from $5000.0 in the prior quarter.
  • Across five years, Gains from Sales and Divestitures topped out at $4.0 million in Q3 2025 and bottomed at $5000.0 in Q2 2024.